Peptides for Weight Loss: What Works in 2026

Peptides have moved from the fringes of performance medicine into mainstream telehealth, and for good reason: several compounds show genuine promise for fat loss through mechanisms entirely different from GLP-1 medications. From growth hormone secretagogues that shift body composition to novel metabolic modulators targeting fat cell enzymes, the landscape has never been more sophisticated — or more important to understand clearly. Here's an evidence-based breakdown of what's actually worth discussing with a provider.

What Are Peptides and Why Are They Used for Fat Loss?

Peptides are short chains of amino acids — essentially smaller versions of proteins — that function as signaling molecules in the body. Because they mimic or modulate naturally occurring biological signals, they can influence specific metabolic pathways with a degree of precision that is difficult to achieve with traditional small-molecule drugs.

In the context of fat loss, the most relevant peptides work primarily through two mechanisms: stimulating growth hormone (GH) release from the pituitary gland (growth hormone secretagogues), or directly targeting adipocyte (fat cell) biology to increase lipolysis and reduce fat storage. Growth hormone itself is a potent lipolytic hormone — it stimulates the breakdown of stored triglycerides in fat cells and promotes the preferential use of fat as fuel. As GH levels naturally decline with age (roughly 14% per decade after age 30), restoring youthful GH pulsatility can meaningfully shift body composition toward less fat and more lean mass.

It's important to distinguish between peptides that stimulate the body's own GH production (secretagogues) and exogenous human growth hormone (HGH) injections. Secretagogue peptides preserve the natural pulsatile release pattern of GH and trigger negative feedback at normal physiological levels, making them significantly safer than supraphysiological HGH doses.

CJC-1295: The Growth Hormone Releasing Hormone Analog

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH), the hypothalamic hormone that signals the pituitary to release GH. Unlike native GHRH, which has a half-life of only a few minutes, CJC-1295 has been modified (particularly in the DAC — Drug Affinity Complex — form) to bind albumin in the bloodstream, extending its half-life to 6–8 days. This creates a sustained elevation in baseline GH and IGF-1 levels rather than a single sharp pulse.

In a phase II clinical trial published in the Journal of Clinical Endocrinology & Metabolism, CJC-1295 DAC produced dose-dependent increases in GH levels of 2–10 fold and elevated IGF-1 by 20–40% above baseline, effects that persisted for up to 28 days after a single injection series. These sustained increases in GH and IGF-1 translate to improved fat oxidation, increased lean mass, enhanced recovery, and — notably — improvements in sleep quality, which itself has significant downstream effects on weight and appetite regulation.

In clinical practice, CJC-1295 is almost always combined with a GHRP (growth hormone releasing peptide) such as Ipamorelin. The GHRH + GHRP combination produces a synergistic amplification of GH release that neither compound achieves alone — GHRH sets the stage and GHRP acts as an amplifier, resulting in GH pulses that more closely mimic the robust peaks seen in younger adults.

Ipamorelin: The Selective GHRP with a Strong Safety Profile

Ipamorelin is a growth hormone releasing peptide (GHRP) — specifically, a ghrelin receptor agonist that stimulates GH release from the pituitary without significantly raising cortisol or prolactin, which are common side effects of older GHRPs like GHRP-2 and GHRP-6. This selectivity makes Ipamorelin one of the most favorable GHRPs available in terms of risk-benefit profile.

When administered subcutaneously (typically at doses of 100–300 mcg), Ipamorelin produces a sharp GH pulse within 30–60 minutes. Combined with CJC-1295 (which maintains elevated baseline GH), the combination creates both sustained elevation and enhanced pulsatile release — a pharmacodynamic pairing that mimics the natural GH release profile of a healthy 25-year-old far more closely than either drug alone.

For body composition purposes, the CJC-1295/Ipamorelin combination has become the most widely prescribed peptide protocol in telehealth settings. Patients typically report improved body composition (particularly reduction in visceral fat and improvement in lean mass), better sleep quality (GH is predominantly released during deep sleep), faster exercise recovery, and improved skin and connective tissue quality over a 3–6 month course. Direct randomized clinical trial data specific to this combination in overweight adults remains limited; much of the supporting evidence is extrapolated from individual compound studies and clinical experience.

AOD-9604: The Fat-Targeting Fragment

AOD-9604 is a modified fragment of human growth hormone (amino acids 176–191 of the HGH C-terminus) that was specifically engineered to isolate the lipolytic effects of HGH while eliminating effects on insulin sensitivity and IGF-1 — the properties that make full HGH potentially problematic at high doses. The name stands for "Anti-Obesity Drug," a designation it earned during research at Monash University in Australia.

Preclinical research demonstrated that AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) through beta-3 adrenergic receptor pathways in adipocytes, independent of the IGF-1 axis. It also appeared to accelerate fat metabolism without causing glucose dysregulation — an important distinction from full HGH.

In early human trials, AOD-9604 showed encouraging results: a 12-week randomized trial with oral AOD-9604 (1 mg/day) demonstrated statistically significant body fat reduction versus placebo. However, larger phase III trials with higher doses of oral formulations did not replicate these results to the degree required for FDA drug approval, and the compound ultimately failed to achieve pharmaceutical-level approval for obesity. This doesn't mean it has no clinical utility — the injectable form at appropriate doses continues to be used in research-oriented clinical settings, and many practitioners incorporate it as part of a broader peptide protocol.

AOD-9604 is considered to have an excellent safety profile: it does not affect blood glucose, IGF-1, or growth-related side effects, making it potentially useful for patients who cannot tolerate GH-stimulating peptides due to pre-existing IGF-1 elevation or diabetes concerns.

Tesamorelin: The Most Clinically Validated GH Peptide

Tesamorelin (brand name Egrifta) holds the distinction of being the only GHRH analog with full FDA approval — granted in 2010 for the reduction of excess abdominal fat in HIV-positive adults with lipodystrophy. This approval is significant because it means tesamorelin has passed the rigorous standards of controlled clinical trials and regulatory review, giving it a stronger evidence base than most research peptides.

In the pivotal trials, tesamorelin 2 mg daily reduced visceral adipose tissue (VAT) by an average of 15–18% versus placebo over 26 weeks, as measured by CT scan. Triglyceride levels also improved significantly. Weight loss was modest (1–2 kg), but the shift in body composition — specifically the reduction in metabolically dangerous visceral fat — was clinically meaningful. Visceral fat is not simply an inert energy depot; it actively secretes pro-inflammatory cytokines and contributes disproportionately to insulin resistance, cardiovascular disease risk, and metabolic syndrome.

While tesamorelin's approval is specific to HIV-related lipodystrophy, its use in the broader context of visceral adiposity is an active area of clinical interest. Patients with significant visceral fat accumulation — particularly those who are metabolically at risk but not yet eligible for GLP-1 medications — may be candidates for tesamorelin under appropriate medical supervision. IGF-1 monitoring is recommended given tesamorelin's robust GH-stimulating effects.

5-Amino-1MQ: A Novel Metabolic Approach

5-Amino-1MQ (5-amino-1-methylquinolinium) represents a newer class of metabolic peptide-adjacent compounds that work through a completely different mechanism: inhibition of the enzyme nicotinamide N-methyltransferase (NNMT). NNMT is expressed predominantly in adipose tissue and plays a key role in regulating cellular energy metabolism. When NNMT activity is high — as it tends to be in obesity — it reduces the availability of S-adenosylmethionine (SAM) and NAD+ in fat cells, effectively suppressing the metabolic rate of adipocytes and promoting fat storage.

5-Amino-1MQ inhibits NNMT, which raises intracellular NAD+ and SAM levels in fat cells, activating the NAD+-dependent deacetylase SIRT1 and downstream energy-sensing pathways including AMPK. The net effect, demonstrated in preclinical studies, is a reduction in the size of fat cells, increased fat oxidation, and prevention of obesity-related metabolic dysfunction even in the context of a high-fat diet.

A 2021 study published in the Journal of Medicinal Chemistry found that 5-Amino-1MQ significantly reduced diet-induced obesity in mouse models, with decreases in body weight and fat mass, improved glucose tolerance, and no observable toxicity. Human clinical trial data remains limited and is an active area of research. Its current use is in research-oriented clinical protocols, and it should be approached as a promising but not yet fully validated compound.

Peptides vs. GLP-1 Medications: How Do They Compare?

The most common question patients ask is whether peptides are better than GLP-1 medications like semaglutide or tirzepatide for weight loss. The honest answer is that for pure weight reduction, GLP-1 medications currently have a substantially stronger evidence base and produce larger average weight losses — 15–22% of body weight with tirzepatide versus 3–8% of body weight estimated for peptide protocols in responsive patients.

However, peptides offer distinct advantages that GLP-1s do not:

• Body composition improvement: GH secretagogues actively increase lean mass while reducing fat, making the weight loss more metabolically favorable. GLP-1 medications can cause loss of muscle mass alongside fat, particularly without resistance training.
• Sleep and recovery benefits: GH peptides improve sleep architecture and recovery, producing systemic benefits beyond fat loss.
• No appetite suppression side effects: Some patients cannot tolerate the nausea, food aversion, or severe appetite suppression associated with GLP-1 medications; peptides work through different mechanisms with a different side effect profile.
• Hormonal restoration: For individuals with age-related GH decline, secretagogue therapy addresses an underlying hormonal deficit rather than simply suppressing hunger.

In practice, peptides and GLP-1s are often used together in comprehensive metabolic programs — the GLP-1 manages appetite and provides cardiovascular benefits while peptides optimize body composition and hormonal status.

Safety Considerations and Medical Supervision

All peptide therapies should be initiated and monitored under medical supervision. Key safety considerations include:

IGF-1 monitoring: GH-stimulating peptides raise IGF-1, which at supraphysiological levels has been associated with increased cancer risk (though no causal link has been established at therapeutic doses). Baseline and periodic IGF-1 testing is standard practice. Peptides are contraindicated in patients with active malignancy.

Blood glucose: While peptides are generally safer than exogenous HGH with respect to insulin resistance, monitoring fasting glucose and HbA1c is appropriate, particularly in pre-diabetic patients.

Peptide quality: The quality of compounded peptides varies significantly between pharmacies. Working with a licensed provider who sources from FDA-registered compounding pharmacies with third-party testing is essential for both safety and efficacy.

Individual variation: Response to peptides varies considerably based on baseline GH status, age, body composition, and genetics. Laboratory testing before and during therapy guides optimal protocols.